

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

*PC 02/20* *577427*

<p style="text-align: center;">Licensee</p> <p>1. Memorial Healthcare Center</p> <p>2. 826 West King Street Owosso, Michigan 48867</p>	<p>In accordance with letter dated <b>April 13, 2012,</b></p> <p>3. License No. 21-11475-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration Date: June 30, 2014</p> <hr/> <p>5. Docket No. 030-02100 Reference No.</p>
--	--

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 35.400</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed sources (Mediphysics Model 6711, OncoSeed and Theragenics Corp. Model 200)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. As needed (not to exceed 300 millicuries of iodine-131)</p> <p>D. Total possession limit for iodine-125 is 150 millicuries. Total possession limit for palladium-103 is 400 millicuries.</p>
--	---	--

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
  - B. Any imaging and localization study permitted by 10 CFR 35.200.
  - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
  - D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.  
21-11475-01

Docket or Reference No.  
030-02100

**Amendment No. 38**

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 826 West King Street, Owosso, Michigan.
11. A. The Radiation Safety Officer for this license is AppaRao Mukkamala, M.D.  
B. The Assistant Radiation Safety Officer for brachytherapy is Arthur Ewald, Ph.D.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized User

Material and Use

Hesham M. El Gayar, M.D.

10 CFR 35.100, 35.200, 35.300 and 35.400.

Jack L. Nettleton, M.D.

10 CFR 35.300 (excluding iodine-131 for hyperthyroid therapy) and 35.400.

Sherrie M. Brooks, D.O.

10 CFR 35.100 and 35.200 (limited to cardiovascular clinical procedures.)

P.B. Lauber, M.D.

10 CFR 35.100, 35.200 and 35.300.

Ahmed M. Akl, M.D.

10 CFR 35.300 and 35.400.

AppaRao Mukkamala, M.D.

10 CFR 35.100, 35.200, 35.300 and 35.400.

M. Rao Tummala, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to hyperthyroid and cardiac dysfunction).

Dindi D. Reddy, M.D.

10 CFR 35.100 and 35.200.

Anant Patel, M.D.

**10 CFR 35.100, 35.200 and 35.300 (limited to oral administration of sodium iodide I-131).**

Gurkan Ege, M.D.

**10 CFR 35.100, 35.200 and 35.300 (limited to oral administration of sodium iodide I-131).**

Gagandeep Singh, M.D.

**10 CFR 35.100, 35.200 and 35.300 (limited to oral administration of sodium iodide I-131).**

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."


**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License No.  
21-11475-01Docket or Reference No.  
030-02100**Amendment No. 38**

14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U. S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Letters dated April 5, 2004 and June 20, 2005; and
- B. Facsimile letters dated September 2, 2005, and September 12, 2005 (with close-out survey dated August 12, 2005).

FOR THE U. S. NUCLEAR REGULATORY COMMISSION

Date MAY 29 2012

By

Bryan A. Parker  
Materials Licensing Branch  
Region III